Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections. Clinical trials showed Vowst significantly ...
The researchers conducted a double-blind, randomized, placebo-controlled trial involving 2,655 adults in 30 countries around the world. The study participants were suffering from primary or recurrent ...
The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a ...
FMT restores gut microbiota balance by transferring stool from healthy donors, mainly for recurrent C. difficile infections. Recent data shows FMT's high efficacy in preventing recurrent C. difficile, ...
A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...
Vowst is a prescription drug that’s used in adults to help prevent Clostridioides difficile (C. diff) infection from coming back after it has been treated. Vowst comes as an oral capsule. Vowst ...
In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal ...
Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known ...
— Greg Vigna, M.D., J.D. SANTA BARBARA, CA, UNITED STATES, August 3, 2023/EINPresswire.com/ -- “Prolonged IV antibiotics are necessary for the treatment of Grade ...
Clostridium difficile caused nearly half a million infections in U.S. patients in 2011, and C. diff infections kill roughly 15,000 Americans each year, according to the Centers for Disease Control and ...
Three recent studies tackled strategies aimed at preventing recurrent Clostridium difficile infection (RCDI). Adding a single dose of bezlotoxumab—a monoclonal antibody that neutralized C difficile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results